Abstract
Interleukin-6 (IL-6) is an inflammatory cytokine with a well-documented role in cancer. The cytokine binds to a membrane-bound IL-6 receptor (IL-6R) and this complex associates with two molecules of the signal transducing protein gp130, initiating intracellular signaling. Whereas gp130 is expressed on all cells of the body, the IL-6R is only found on some cells, mainly hepatocytes and several leukocytes. Cells, which only express gp130 and no IL-6R, cannot respond to IL-6. We have shown that the IL-6R exists as a soluble protein generated by limited proteolysis of the membrane-bound receptor or by translation from an alternatively spliced mRNA. The complex of soluble IL-6R (sIL-6R) and IL-6 can bind to gp130 on cells that lack the membrane-bound IL-6R and trigger gp130 signaling. We have named this process trans-signaling. We review data that show that IL-6 uses classical signaling via the membrane-bound receptor and trans-signaling via the soluble receptor in physiological and pathophysiological situations. We have developed designer cytokines, which specifically enhance or inhibit IL-6 trans-signaling. These designer cytokines have been shown to be extremely useful in therapeutic applications such as blockade of chronic inflammation and cancer.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
- Leukemia Inhibitory Factor
- Soluble Cytokine Receptor
- Soluble Gp130
- Crohn Disease Patient
- Chronic Disease Progression
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Aasland D, Oppmann B, Grötzinger J, Rose-John S, Kallen K-J (2002) The upper cytokine binding module and the Ig-like domain of the leukaemia inhibitory factor (LIF) receptor are sufficient for a functional LIFR complex. J Mol Biol 315:637–646
Aasland D, Schuster B, Grötzinger J, Rose-John S, Kallen K-J (2003) Analysis of the leukemia inhibitory factor receptor functional domains by chimeric receptors and cytokines. Biochemistry 42:5244–5252
Abel S, Hundhausen C, Mentlein R, Berkhout TA, Broadway N, Siddall H, Dietrich S, Muetze B, Kallen KJ, Saftig P, Rose-John S, Ludwig A (2004) The transmembrane CXC-chemokine CXCL16 is expressed on vascular cells and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172:6362–6372
Althoff K, Reddy P, Peschon J, Voltz N, Rose-John S, Müllberg J (2000) Contribution of the amino acid sequence at the cleavage site to the cleavage pattern of transmembrane proteins. Eur J Biochem 267:2624–2631
Althoff K, Müllberg J, Aasland D, Voltz N, Kallen KJ, Grötzinger J, Rose-John S (2001) Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J 353:663–672
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF (2000) Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells. Nat Med 6:583–588
Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ (2001) Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic cells. Proc Natl Acad Sci U S A 98:1757–1762
Barton BE, Jackson JV (1993) Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 61:1496–1499
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501
Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220
Bleier JI, Pillarisetty VG, Shah AB, DeMatteo RP (2004) Increased and long-term generation of dendritic cells with reduced function from IL-6-deficient bone marrow. J Immunol 172:7408–7416
Campard D, Vasse M, Rose-John S, Poyer F, Lamacz M, Vannier JP (2006) Multilevel regulation of IL-6R by IL-6/sIL-6R fusion protein according to the primitiveness of the peripheral blood-derived CD133+ cells. Stem Cells 24:1302–1314
Chomarat P, Banchereau J, Davoust J, Palucka AKNI (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1:510–514
Curnow SJ, Scheel-Toellner D, Jenkinson W, Raza K, Durrani OM, Faint JM, Rauz S, Wloka K, Pilling D, Rose-John S, Buckley CD, Murray PI, Salmon M (2004) Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 173:5290–5297
Diao H, Kohanawa M (2005) Endogenous interleukin-6 plays a crucial protective role in streptococcal toxic shock syndrome via suppression of tumor necrosis factor alpha production. Infect Immunol 73:3745–3748
Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer JB, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5:752–760
Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, El-Bdaoui H, Schmitt E, Bopp T, Kallen KJ, Herz U, Schmitt S, Luft C, Hecht O, Hohlfeld M, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Rose-John S, Renz H, Neurath MF, Galle PR, Finotto S (2005) The IL-6R alpha chain controls lung CD4+CD4+CD25+T regulatory cell development and function during allergic airway inflammation in vivo. J Clin Invest 115:313–325
Fischer M, Goldschmitt J, Peschel C, Kallen KJ, Brakenhoff JPJ, Wollmer A, Grötzinger J, Rose-John S (1997) A designer cytokine with high activity on human hematopoietic progenitor cells. Nat Biotech 15:142–145
Guillet C, Lelievre E, Plun-Favreau H, Froger J, Chabbert M, Hermann J, Benoit de Coignac A, Bonnefoy JY, Gascan H, Gauchat JF, Elson G (2002) Functionally active fusion protein of the novel composite cytokine CLC/soluble CNTF receptor. Eur J Biochem 269:1932–1941
Hacker C, Kirsch RD, Ju X-S, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4:380–386
Hegde S, Pahne J, Smola-Hess S (2004) Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-κB binding activity and CCR7 expression. FASEB J 18:1439–1441
Hoebe K, Janssen E, Beutler B (2004) The interface between innate and acquired immunity. Nat Immunol 10:971–974
Humphrey RK, Beattie GM, Lopez AD, Bucay N, King CC, Firpo M, Rose-John S, Hayek A (2004) Maintenance of pluripotency in human embryonic stem cells is Stat3 independent. Stem Cells 22:522–530
Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen K-J, Rose-John S, Ludwig A (2003) The disintegrin-like metalloproteinase ADAM 10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102:1186–1195
Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA (2001) Control of leukocyte infiltration during inflammation: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment. Immunity 14:705–714
Jones SA (2005) Directing transition from innate to acquired immunity: Defining a role for IL-6. J Immunol 175:3464–3468
Jones S, Richards PJ, Scheller J, Rose-John S (2005) IL-6 Transsignaling: the in vivo consequences. J Interferon Cytokine Res 25:241–253
Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem 268:160–167
Kallen K-J (2002) The role of transsignalling via the agonistic soluble IL-6 receptor. Biochim Biophys Acta 1592:323–343
Kallen K-J, Grötzinger J, Lelièvre E, Vollmer P, Aasland D, Renné C, Müllberg J, Meyer zum Büschenfelde K-H, Gascan H, Rose-John S (1999) Receptor recognition sites of cytokines are organized as exchangeable modules: transfer of the LIFR binding site from CNTF to IL-6. J Biol Chem 274:11859–11867
Kallen K-J, Grötzinger J, Rose-John S (2000) New perspectives in the design of cytokines and growth factors. Trends Biotechnol 18:455–461
Klouche M, Bhakdi S, Hemmes M, Rose-John S (1999) Novel path of activation of primary human smooth muscle cells: upregulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 163:4583–4589
Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4:96–100
Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027
März P, Cheng J-C, Gadient RA, Patterson P, Stoyan T, Otten U, Rose-John S (1998) Sympathetic neurons can produce and respond to Interleukin-6. Proc Natl Acad Sci U S A 95:3251–3256
März P, Otten U, Rose-John S (1999) Neuronal activities of IL-6 type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 11:2995–3004
Matthews V, Schuster B, Schütze S, Bußmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen K-J, Rose-John S (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278:38829–38839
McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, Williams JD, Rose-John S, Jones SA, Topley N (2003) Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 112:598–607
McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA (2005) IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102:9589–9594
Mitani H, Katayama N, Araki H, Ohishi K, Kobayashi K, Susuki H, Nishii H, Masuya M, Yasukawa K, Minami N, Shiku H (2000) Activity of interleukin-6 in the differentiation of monocytes to macrophages and dendritic cells. Br J Haematol 109:288–295
Mitsuyama K, Tomiyasu N, Suzuki A, Takaki K, Takedatsu H, Masuda J, Yamasaki H, Matsumoto S, Tsuruta O, Toyonaga A, Sata M (2005) A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 143:125–131
Müllberg J, Althoff K, Jostock T, Rose-John S (2000) The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 11:27–38
Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA (2003) Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171:3202–3209
Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036
Peters M, Schirmacher P, Goldschmitt J, Odenthal M, Peschel C, Dienes HP, Fattori E, Ciliberto G, Meyer zum Büschenfelde KH, Rose-John S (1997) Extra-medullary expansion of hematopoietic progenitor cells in IL-6/sIL-6R double transgenic mice. J Exp Med 185:755–766
Peters M, Müller A, Rose-John S (1998) Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92:3495–3504
Pflanz S, Tacken I, Grötzinger J, Jacques Y, Dahmen H, Heinrich PC, Müller-Newen G (1999) A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett 450:117–122
Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 172:2225–2231
Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, Yamamoto N, Ehrmann M, Williams AS, Rose-John S, Topley N, Jones SA (2006) Baculovirus expression and functional characterization of a recombinant human soluble gp130 isoform and its role in the regulation of L-6 transsignaling. Arthr Rheumat 54:1662–1672
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A (1997) Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315–325
Rose-John S (2001) Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv Exp Med Biol 495:145–151
Rose-John S (2002) GP130 stimulation and the maintenance of stem cells. Trends Biotechnol 20:417–419
Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300:281–290
Scheller J, Schuster B, Hölscher C, Yoshimoto T, Rose-John S (2005) No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun 326:724–728
Sun Y, März P, Otten U, Ge J, Rose-John S (2002) The effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons. Biochem Biophys Res Commun 295:532–539
Taga T, Kishimoto T (1997) gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819
Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581
Teague TK, Schaefer BC, Hildeman D, Bender J, Mitchell T, Kappler JW, Marrack P (2000) Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. J Exp Med 191:915–926
Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J (1991) Intratracheal injection of endotoxin and cytokines. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 138:1097–1102
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rose-John, S., Schooltink, H. (2007). Cytokines Are a Therapeutic Target for the Prevention of Inflammation-Induced Cancers. In: Senn, HJ., Kapp, U. (eds) Cancer Prevention. Recent Results in Cancer Research, vol 174. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-37696-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-37696-5_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-37695-8
Online ISBN: 978-3-540-37696-5
eBook Packages: MedicineMedicine (R0)